Radio Advisory

This week, we are revisiting episode 1 of our "Hospital of the Future series” which was initially released all the way back in November 2022. The majority of hospitals are predicted to have negative margins in 2022, marking the worst year financially for hospitals since the beginning of the Covid-19 pandemic. In Part 1 of Radio Advisory’s Hospital of the Future series, host Rachel (Rae) Woods invites healthcare business experts Monica Westhead, Aaron Mauck, and Colin Gelbaugh to discuss why factors like workforce shortages, post-acute financial instability, and growing competition are contributing to this troubling financial landscape and how hospitals are tackling these problems. Links: 'The most difficult year': Why hospital finances are so strained Our Financial Impact playlist Services at risk of shifting from the hospital setting What you need to know about out-of-market travel for surgery 10 takeaways from our cost management intensive Take our RN workforce survey at: advisory.com/RNsurvey Learn more about Advisory Board On-Demand Courses

(New/bonus content starts at 24:11. First part of episode originally aired October 5, 2021.) This week, Radio Advisory is bringing you an encore of Ep. 91: We need to talk about maternal health in America, where host Rachel (Rae) Woods invites Advisory Board Expert Darby Sullivan and Optum Director of social responsibility Callie Chamberlain to discuss the dire state of maternal health in America. Following the original episode, in a special bonus segment, host Rae Woods brings back Advisory Board health equity expert Darby Sullivan and invites women’s health expert Gaby Marmolejos to discuss why maternal health, and women’s health more broadly, are only getting worse. In the conversation, they discuss what is driving poor maternal outcomes and why there needs to be a massive shift in how the industry thinks about maternal health moving forward. This episode was recorded before the FDA approved Zurzuvae (zuranolone), the first ever pill to treat post-partum depression. Postpartum depression is a condition that affects one in eight new mothers. Previously, the only treatment available was an IV infusion approved by the FDA, which required patients to be in the hospital for 2.5 days. The move underscores the industries' need to focus on behavioral health in the postpartum period and on women’s health more broadly. Links: Ep. 91: We need to talk about maternal health in America Revisiting our Dobbs v. Jackson predictions, 1 year later What's driving the 'shocking disparities' in maternal health outcomes? Around the nation: FDA approves first pill for postpartum depression Addressing the Root Causes of Maternal Health Inequity [JAMA] Trends in Maternal Mortality and Severe Maternal Morbidity During Delivery-Related Hospitalizations in the United States, 2008 to 2021 Learn more about Advisory Board On-Demand Courses Visit advisory.com/workforce to get research and insights that will help you understand the current challenges providers are facing and learn how technology – including platforms you may already have – can address healthcare's biggest staffing and care delivery challenges. Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.

In recent years, there has been a major influx of new genetic tests that have hit the market. While these tests promise to revolutionize diagnostics and treatment decision-making, the industry needs to overcome a variety of reimbursement and logistical barriers to achieve any goals for genomics at scale. In this episode, guest host and Advisory Board expert partner Devin Airey invites Mark Gardner, the SVP of Genomic Medicine and Oncology at Quest Diagnostics, and Dan Edelstein, President and CEO of Haystack Oncology, to discuss their vision for genomics at scale. Throughout the conversation, they discuss increased attention from providers and purchasers, how to integrate new genomics technology into patient care, and how to address opportunities and concerns in the market. Links: 6 questions shaping the future of oncology screening and diagnostics What liquid biopsies could mean for cancer treatment and disease monitoring Home | Quest Diagnostics Haystack Oncology – Better decisions with better MRD testing Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio [Webinar] Consumer insights decision makers should lead with in 2023 (August 24 | 3-4pm ET)

(New/bonus content starts at 19:50.) This week, Radio Advisory is bringing you an encore edition of 4 ways to prevent a physician shortage, which originally aired in May 2022. Host Rachel (Rae) Woods invites Advisory Board experts Daniel Kuzmanovich and Sebastian Beckmann to discuss the threats and realities of a physician shortage. Following the original podcast, in a special bonus segment, host Rae Woods passes the mic to Eliza Dailey and Sydney Moondra to discuss how Advanced practice providers (APPs) are, and will continue to, radically transform the physician landscape. Links: How to prevent a primary care shortage Deploying APPs Autonomously Physician employment is changing. What does that mean for the industry? Is there really a primary care shortage? Four keys to maximizing advanced practice provider (APP) ROI Ep. 96 Why the headlines are wrong about physician shortages Learn more and register for the 2023 Advisory Board Clinical Innovation Summit [August 22-23, 2023]

While value-based care has been at the forefront of industry conversations in the last decade, there are still a lot of questions about how to successfully create and thrive as a value-based enterprise. At the end of June, around 300 healthcare leaders gathered at Advisory Board’s Value-Based Care Summit with one shared goal: make the next 10 years of VBC more impactful from the last. As part of the event, the Radio Advisory team orchestrated a live podcast recording with three renowned leaders at the helm of very different organizations – all trying to build value-based enterprises. In this special live episode of Radio Advisory, host Rachel (Rae) Woods invites Rob Mayer, senior vice president and GM of Optum Insight Clinical Solutions; Laurie Sicaeros, Chief Strategy Officer at Memorial Care Health System; and Rushika Fernandopulle, Co-Founder and Former CEO of Iora Health, to discuss building a value-based enterprise, what defines success, and what capabilities and assets are needed to succeed. Links: The climb to value-based care Introduction to the series: Envisioning paths to nationwide VBC Ep. 166: Employer series: The role of employers in value-based care Ep. 113: What it will take to get to meaningful risk Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.

In the last two weeks, we discussed the use of consumer data and how the FTC is using its power to respond to data privacy concerns. While there are stakeholders who are taking action in response, we wanted to explore a key question: what happens when the concerns raised are left unchecked? Following the 2022 Dobbs v. Jackson decision that overturned Roe v. Wade, we seem to have a test case. In part three of Radio Advisory’s series on consumer data, host Rachel Woods invites Advisory Board experts Ty Aderhold and John League to discuss how the Dobbs decision impacts conversations around data privacy and how healthcare leaders should be thinking about protecting patient reproductive data. Links: Ep. 170: Data privacy and the FTC: Who is working to protect your data? Ep. 169: Innovative or invasive? How consumer data is changing healthcare Revisiting our Dobbs v. Jackson predictions, 1 year later Ep. 121: Researchers react: Roe is overturned Roe v. Wade is overturned. Are you ready to answer these questions? Dobbs v. Jackson: Key impacts across health care Learn more about Advisory Board On-Demand Courses

In the last episode, we discussed how different industry stakeholders are taking advantage and navigating the challenges of the use of consumer data in healthcare. While the industry wrestles with some concerns about data privacy, the question remains: who is working to protect the data of consumers and patients? In part two of Advisory Board’s series on consumer data, host Rachel Woods invites Advisory Board experts Ty Aderhold, Sara Zargham, and Paul Trigonoplos to discuss one stakeholder that is making moves to protect data privacy: the FTC. In the conversation, they explore recent regulatory actions taken by the FTC and what this means for the industry. Links: Ep. 169: Innovative or invasive? How consumer data is changing healthcare Around the nation: FTC issues warning about usage of consumers' biometric data Winners and losers from FTC's increased focus on consumer privacy in healthcare Anonymity in the digital age [HealthAffairs.org] Widespread Third-Party Tracking On Hospital Websites Poses Privacy Risks For Patients And Legal Liability For Hospitals [FTC.gov] FTC Warns Health Apps and Connected Device Companies to Comply With Health Breach Notification Rule [nytimes.com] How Companies Learn Your Secrets Check out this recent Advisory Board blog post about how to address 5 common challenges seniors face in cancer care

For years, consumers have felt the effects of the increased use of their data. From receiving targeted advertisements to personalized recommendations online, it is no secret that giants in various industries are taking advantage of complex consumer data. But how does this look in the healthcare space? In part one of a new three-part series on consumer data, host Rachel Woods invites Advisory Board experts Solomon Banjo and Ty Aderhold to discuss how various industry players are taking advantage and navigating the challenges of the use of consumer data in healthcare. In the conversation, they explore exactly what kind of information is being used, what this means for various stakeholders, and how the rising use of consumer health data is poised to radically change the industry. Links: HHS: How to handle reproductive health data after Dobbs v. Jackson 'Deeply troubled': Security experts worry about Facebook trackers on hospital sites Around the nation: FTC issues warning about usage of consumers' biometric data Winners and losers from FTC's increased focus on consumer privacy in healthcare How Companies Learn Your Secrets Learn more about Advisory Board’s upcoming webinar on key innovations in cancer care for patients by visiting https://www.advisory.com/resources/events

For years Advisory Board has been researching how technology and macro-economic forces are shaping clinical decision-making, and recent advances in large language models and AI have the potential to make an impact like we’ve never seen before. In this episode, guest host and Advisory Board life sciences expert Soloman Banjo invites Advisory Board expert Amanda Okaka and Optum’s Senior Vice President of Clinical Innovation Dr. Kevin Larson to discuss the technologies that will change clinical decision-making in the next decade, its implications, and what organizations should be thinking about as they integrate them into clinical workflows. Links: How clinicians will use evidence in 2032 5 takeaways from our expert panel on technology's role in the future of clinical decision-making The future of clinical decision-making at the institutional level Learn more about Advisory Board’s upcoming webinar on key innovations in cancer care for patients by visiting https://www.advisory.com/resources/events Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.

With a variety of new (and expensive) therapies in the pipeline for 2023, it is understandable that the industry is feeling anxiety over the rise of high-cost drugs. However, there is not one-size-fits all solution. Industry stakeholders must consider and respond differently to each drug type. In this episode, host Rachel (Rae) Woods invites Advisory Board pharmacy experts Gina Lohr and Chloe Bakst to discuss how industry stakeholders are thinking about different high-cost drugs and how they can prepare for the future. Links: Ep. 134: Can Mark Cuban solve our drug cost problems? Ep. 159: Ozempic, Wegovy, and our questions on weight management drugs Why 'cash' pharmacies are booming—and what it means for healthcare These 4 groups will benefit most from drug pricing reform Ultra high-cost drugs Contracts to Mitigate Risks from Ultra High-Cost Drugs Learn more about Advisory Board On-Demand Courses